BPC-157: Complete Research Guide for Gut Protection & Recovery

What Is BPC-157?

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a naturally occurring protein sequence found in human gastric juice. The 15-amino acid sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) has been extensively studied in preclinical models for gastroprotective, wound-healing, and angiogenic properties.

Molecular Profile

• Sequence: 15-amino acid pentadecapeptide
• Molecular weight: 1,419.56 Da
• Also known as: PL-10, Bepecin, PLD-116
• Stability: Highly stable at physiological pH; resistant to acid degradation
• Origin: Derived from human gastric juice protein

Key Mechanisms of Action

Gastric Cytoprotection

BPC-157 is named for its gut-protective properties. It upregulates cytoprotective genes in gastric mucosal cells, protects against ethanol-induced and NSAID-induced ulcers in preclinical models, and maintains gut barrier integrity under stress conditions.

This is why BPC-157 is paired with GLP compounds in the Clavicular Stack — GLP-1 receptor agonists cause significant GI side effects (nausea, gastroparesis, reduced motility). BPC-157 directly addresses the gastric mucosa stress.

Nitric Oxide (NO) Pathway

BPC-157 modulates the NO system — upregulating eNOS activity and NO production in blood vessels. This contributes to:

• Vasodilation and improved local blood flow
• Angiogenesis (new blood vessel formation)
• Accelerated wound healing at injury sites

Tendon, Ligament & Connective Tissue Repair

Preclinical studies show BPC-157 accelerates healing of:

• Achilles tendon transections (rats): significantly faster tensile strength recovery
• MCL and ACL ligament injuries: enhanced collagen organization
• Muscle tears: upregulated growth factor expression at injury site

Mechanism: BPC-157 upregulates VEGF (vascular endothelial growth factor) and EGF receptor expression, promoting vascularization of healing tissue.

Angiogenesis

Through VEGF upregulation and direct endothelial cell stimulation, BPC-157 promotes the formation of new capillary networks in healing tissue — a critical rate-limiting step in connective tissue repair.

Gut Motility & the Gut-Brain Axis

BPC-157 affects the enteric nervous system, modulating serotonin release and dopamine pathways. Preclinical models suggest it may counteract GI disruptions to gut motility.

Research Dosing Reference

From Published Preclinical Literature

• Gastric ulcer models: 10 mcg/kg (rat), once daily
• Tendon healing models: 10 mcg/kg s.c., twice daily
• Wound healing: 10-100 ng/kg topically or s.c.

Reconstitution Protocol (10mg Vial)

• Add 10mL bacteriostatic water → 1mg/mL (1000mcg/mL)
• For 250mcg research dose: draw 0.25mL
• For 500mcg research dose: draw 0.5mL

Storage: Lyophilized: stable at room temperature. Reconstituted: 2-8°C, use within 4-6 weeks.

Why BPC-157 Is in the Clavicular Stack

GLP-1 receptor agonists including Retatrutide cause clinically significant nausea, vomiting, and gastroparesis — particularly during dose escalation. BPC-157 is included specifically for:

• Gastric mucosal protection: Directly counteracts GLP-induced gut stress
• Nausea reduction: Enteric nervous system modulation
• General recovery: Connective tissue and tendon repair during body recomposition
• Angiogenesis: Blood vessel support for tissue health during fat loss phase

Research Applications

• Gastroprotection models (ethanol, NSAID, ischemia)
• Tendon/ligament healing preclinical research
• Angiogenesis and wound healing studies
• Gut-brain axis research
• GI protection during peptide co-administration studies

Research-grade BPC-157 10mg available from Clavicular Stack. For laboratory research use only.